文献速递中医内科中药与中成药合理使用

中药治疗阿尔茨海默病系统评价再评价

An Overview of Systematic Reviews of Chinese Herbal Medicine for Alzheimer's Disease.
PubMed 文献 · Front Pharmacol · 2021-11-26

结果显示中药单用或辅助治疗可能改善AD患者认知功能且不良事件较少,但方法学质量极低、证据质量低或极低,结论需谨慎。

要点

  • 中药单用或联合西药可能改善AD患者认知功能评分。
  • 中药单用或辅助治疗不良事件少于单用西药。
  • 纳入系统评价方法学质量极低,证据质量低或极低。

核心结论

  • 当前证据提示中药可能有益于改善阿尔茨海默病患者的认知功能。
  • 因方法学缺陷和证据质量低,对上述结论应保持谨慎。
  • 仍需高质量随机对照试验确认中药治疗AD的疗效与安全性。

研究设计与样本

  • 本研究为系统评价再评价,检索6个中英文电子数据库至2021年4月31日。
  • 采用AMSTAR-2评估方法学质量,采用GRADE评估结局证据质量。

主要发现

  • 与单用西药相比,中药辅助治疗在改善MMSE、ADAS-Cog和CDR评分方面显示显著效果。
  • 中药单用同样在改善MMSE、ADAS-Cog和CDR评分方面显示显著效果。
  • 在日常生活活动能力方面,中药单用或联合西药均无明显效果。
  • 在总有效率方面,中药单用及联合西药均显示显著效果。
  • 9篇系统评价提示中药辅助治疗或单用不良事件少于西药。

关键数值与推荐

  • AMSTAR-2评估显示纳入系统评价的方法学质量极低。
  • GRADE评估显示主要结局的证据质量低或极低。

临床怎么用

  • 可将中药作为AD认知功能改善的辅助或单用选项,但需向患者说明证据质量低。
  • 使用中药时需关注其安全性,现有系统评价提示不良事件少于西药。
  • 临床决策应结合患者具体情况,不宜仅凭低质量证据推荐。

局限性

  • 纳入系统评价的方法学质量极低。
  • 主要结局的证据质量低或极低。
  • 需要高质量随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Multiple systematic reviews (SRs) have been conducted to evaluate the efficacy and safety of Chinese herbal medicine (CHM) in patients with Alzheimer's disease (AD). Here, we aim to perform an overview to assess the methodological quality and quality of evidence of the SRs to provide convincing data on the treatment of AD with CHM. Method: Six electronic databases including Chinese and English were searched, until April 31, 2021. Two researchers independently screen documents and extract data according to the predesigned rules. A Measure Tool to Assessment System Reviews 2 (AMSTAR-2) was used to investigate the methodological quality, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was used to determine the quality of evidence for outcomes. Results: Twelve qualified SRs including 163 randomized controlled trials were reviewed. The methodological quality of the included SRs was considered extremely low assessed through AMSTAR-2. Compared with western medicines (WM) alone, CHM as an adjuvant treatment has shown significant effects in improving Mini-mental State Examination, Alzheimer's Disease Assessment Scale-Cognitive, and Clinical Dementia Rating scores. The same is true for CHM alone. Regarding the effect on Activities Daily Living, neither the single CHM nor the combination with WM has an obvious effect. For the total effective rate, both single CHM and the combination with WM shown significant effects. Nine SRs suggested that CHM as adjuvant therapy or single-use had fewer adverse events than WM. Additionally, the quality of evidence for the main outcome was reviewed as low or extremely low according to GRADE profiler data. Conclusion: Current evidence suggests that CHM may be beneficial in improving the cognitive function of AD patients. However, we should be cautious about the evidence due to methodological flaws and low quality. High-quality RCTs are further needed to confirm the efficacy and safety of CHM for AD.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu N, Zhang T, Sun J, et al. An Overview of Systematic Reviews of Chinese Herbal Medicine for Alzheimer's Disease. Front Pharmacol. 2021. PMID: 34899316. doi:10.3389/fphar.2021.761661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。